Skip to content

Study · Not a test of the peptide alone · 2011

4 results

In vitro and in vivo pro-angiogenic effects of thymosin-β4-derived peptides.

Dettin M, Ghezzo F, Conconi MT, Urbani L, D'Auria G, Falcigno L, Guidolin D, Nico B, Ribatti D, Di Bello C, Parnigotto PP

Cellular immunology29 Jul 2011Cited by 4 (Europe PMC)

PMID21872226 (opens in a new tab)DOI10.1016/j.cellimm.2011.07.008 (opens in a new tab)PepBankPUB-21872226
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Activity measurement

    Synthetic peptides derived from Tβ4 exerted pro-angiogenic effects in vivo.

    In plain wordsIn animals, short pieces of thymosin beta‑4 showed pro-angiogenic effects.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseIn vivo pro-angiogenic effect of Tβ4-derived peptides
    Study

    n: not reported in source

    Outcome group
    Angiogenesis · Cardiovascular

    Source sentences

    Summary
    Tβ4-derived peptides exert both in vitro and in vivo pro-angiogenic effects
    1 context sentence
    Summary · context
    In this work, we have designed and synthesized three peptide sequences containing the N-terminus (TYB4-n), the central part (TYB4-i) or the C-terminus (TYB4-c) of Tβ4.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Activity measurement

    Synthetic peptides derived from Tβ4 exerted pro-angiogenic effects in vitro.

    In plain wordsIn lab tests, short pieces of thymosin beta‑4 showed pro-angiogenic effects in cells.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseIn vitro pro-angiogenic effect of Tβ4-derived peptides
    Study

    n: not reported in source

    Outcome group
    Angiogenesis · Cardiovascular

    Source sentences

    Summary
    Tβ4-derived peptides exert both in vitro and in vivo pro-angiogenic effects
    1 context sentence
    Summary · context
    In this work, we have designed and synthesized three peptide sequences containing the N-terminus (TYB4-n), the central part (TYB4-i) or the C-terminus (TYB4-c) of Tβ4.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    The in vitro effect of the Tβ4-derived peptides seemed related to activation of several signalling pathways and was positively modulated by the N-terminus of Tβ4.

    In plain wordsIn cells, the effect of the thymosin beta‑4 pieces seemed to involve several signalling pathways and was increased by the N-terminal piece.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableSignalling pathways and N-terminus modulation of in vitro effect
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    (iii) their in vitro effect seem to be related to the activation of several signaling pathways and is positively modulated by the N-terminus of Tβ4.
    1 context sentence
    Summary · context
    In this work, we have designed and synthesized three peptide sequences containing the N-terminus (TYB4-n), the central part (TYB4-i) or the C-terminus (TYB4-c) of Tβ4.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  4. 04LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Other

    Each Tβ4-derived fragment reproduced the native conformation of Tβ4.

    In plain wordsIn lab tests, each thymosin beta‑4 fragment kept the shape of the full peptide.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableNative conformation of Tβ4-derived fragments
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    each fragment reproduces the native conformation

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.